StockTake: White Cliff Minerals
White Cliff Minerals has added another drill rig to its drilling program at the Rae copper project in Canada.
White Cliff Minerals has added another drill rig to its drilling program at the Rae copper project in Canada.
A review of legacy datasets and airborne VTEM survey findings has confirmed the presence of a discrete conductor at Thowagee, which TAR has elevated to a priority target.
Albion Resources has entered a deal with Capricorn Metals for its Mongers Lake gold project in the West Australian Murchison.
Today’s crop of last minute quarterly ‘homework’ isn’t hiding too much of the nasty stuff synonymous with ‘just-in-time’ lodgers.
The ASX is set to rise, with the upcoming election and Federal Reserve meeting. Amazon and Intel surged after reporting strong earnings.
Bank stocks, including CBA, have fallen on the ASX today, while gold dips below US$2600 and Nvidia hits record highs.
Tylah Tully looks at a multi-thousand metre Greenvale Energy drill campaign now underway at its Oasis uranium project in Queensland.
Power Minerals will carry out drilling to find a source of industrial water, which is essential for direct lithium extraction at Pocitos project within the Rincon JV.
Tech-centric capital fund Bailador Technology Investments delivers standout FY25, driven by strategic capital deployment and strong growth across its private portfolio.
Prescient Therapeutics is entering a critical stage with clinical progress, regulatory tailwinds and commercial opportunity converging.
Nova Minerals has strengthened ties with key Alaskan lawmakers and other stakeholders during a board visit to its 9.9Moz Estelle gold and critical minerals project.
As listed players like Vita Life Sciences and EZZ chase wellness demand, Complementary Medicines Group is stepping up with a clinically backed supplement targeting one of Australia’s most common pain points.
Octava Minerals has an option to acquire the Federation copper-silver-zinc project in Tasmania where historical drilling returned significant intersections.
Neurizon submits a formal response to the US FDA addressing a clinical hold on its investigational new drug (IND) application for lead drug NUZ-001.
Original URL: https://www.themercury.com.au/business/stockhead/page/11